Targeted Drug Delivery through Conjugation

With more than 30 years of experience in bio-conjugation, SAFC has become a leading expert for the conjugation of highly active molecules.

Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugation technology uses monoclonal antibodies or other biologics to deliver conjugated Highly Potent APIs (HPAPIs) to targeted cells. In conjugated form, the HPAPI exhibits more selective cytotoxicity, thereby, sparing non-target cells from many of the toxic effects. Customers are quickly adapting these complex technologies and employing them to develop new oncology products that are more targeted and exponentially more powerful.

Our offer includes:

  • Development and manufacture of commercial scale HPAPIs, linkers, payload and conjugates
  • Suite dedicated to conjugation of HPAPIs to biologic molecules
  • Working with the market leaders in linker technology
  • Conjugation of non-potent APIs to biologic carriers, including polyamino acids or polynucleotides
  • Extensive analytical tests for APIs and biological assays
  • Commercial suite coming online in 2015

A Comprehensive Approach to ADC CMC

To learn about SAFC’s comprehensive approach enabling efficient delivery of clinical test material for ADC manufacture, click here. The video presentation was recorded live during ibc’s BDP Week 2014 and takes 30 minutes.

Register for our complementary live webinar on September 4, 2014: “Successful Strategies in the Development and Technology Transfer of Antibody-Drug Conjugates

Contact SAFC

Contract Manufacturing Inquiries
For product/service inquiries, quotes or information requests

Contact our ADC experts directly at conjugation@sial.com